
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep Ltd's development of eftilagimod alfa (efti) has demonstrated significant clinical efficacy, particularly in the treatment of non-small cell lung cancer (1L NSCLC), where it has notably increased the overall response rates (ORR) for patients with low tumor proportion score (TPS <1%) by 22.2% over historical treatment rates. The company's strong intellectual property portfolio surrounding efti enhances its potential for combination therapies, particularly with existing PD-(L)1 franchise treatments, paving the way for broader market applications and partnerships. Overall, the combination of promising clinical trial results and robust product development strategies contributes to a positive outlook for Immutep's stock performance.
Bears say
Immutep Ltd faces significant challenges in advancing its lead product candidate, eftilagimod alfa (efti), as the probability of success for its registrational Phase three clinical trial in non-small cell lung cancer has been reduced to just 30% due to underwhelming clinical results. Additionally, there are concerns regarding the efficacy of eftilagimod in comparison to historical data, particularly as results from the INSIGHT-003 trial are expected to be inferior due to a higher number of low TPS patients, which may lead to diminished overall efficacy metrics. Furthermore, LAG-3 antagonists, including Immutep's offerings, have historically delivered mixed results in lung cancer, creating a perceptual headwind that diminishes investor confidence in their potential to change clinical practice.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares